The molecular diagnostics (i.e. chromosomal or genetic markers) associated with the brain Tumour during a Cancer Care Spell, taken from the World Health Organisation classification.
National Codes:
1 | Evidence of IDH1 or IDH2 mutation (Retired 01 April 2017) |
2 | Evidence of methylation of the MGMT gene CpG island (Retired 01 April 2017) |
3 | Evidence of total loss of 1p and 19q (Retired 01 April 2017) |
4 | Evidence of KIAA 1549-BRAF fusion gene (Retired 01 April 2017) |
5 | Other (Retired 01 April 2017) |
06 | Evidence of ALK rearrangement |
07 | Evidence of native ALK |
08 | Evidence of ATRX mutation |
09 | Evidence of wt ATRX |
10 | Evidence of BRAF V600E mutation |
11 | Evidence of wt BRAF |
12 | Evidence of KIAA1549-BRAF fusion |
13 | Evidence of BRAF/RAF1 mutations, or fusions involving genes other than KIAA1549 |
14 | Evidence of C11orf95-RELA fusion |
15 | Evidence of native C11orf95 and RELA |
16 | Evidence of amplification or fusion of C19MC locus (chr.19q13.42) |
17 | Evidence of unaltered C19MC locus (chr.19q13.42) |
18 | Evidence of CDK4/6 amplification |
19 | Evidence of CDK4/6 normal copy number |
20 | Evidence of CDKN2A locus homozygous deletion |
21 | Evidence of CDKN2A locus normal copy number |
22 | Evidence of CCND1/2/3 amplification |
23 | Evidence of CCND1/2/3 normal copy number |
24 | Evidence of CTNNB1 mutation |
25 | Evidence of wt CTNNB1 |
26 | Evidence of amplification of EGFR |
27 | Evidence of mutation / rearrangement of EGFR |
28 | Evidence of unaltered EGFR |
29 | Evidence of EWSR1-FLI1 fusion |
30 | Evidence of native EWSR1 and FLI1 |
31 | Evidence of FGFR1 mutation / rearrangement / fusio |
32 | Evidence of unaltered FGFR1 |
33 | Evidence of H3F3A/H3F3B (H3.3) K27M mutation |
34 | Evidence of H3F3A/H3F3B (H3.3) wt K27 |
35 | Evidence of H3F3A/H3F3B (H3.3) G34R/V mutation |
36 | Evidence of H3F3A/H3F3B (H3.3) wt G34 |
37 | Evidence of HIST1H3B K27M mutation |
38 | Evidence of HIST1H3B wt K27 |
39 | Evidence of HIST1H3C K27M mutation |
40 | Evidence of HIST1H3C wt K27 |
41 | Evidence of ID2 amplification |
42 | Evidence of ID2 normal copy number |
43 | IDH1 (codon 132) or IDH2 (codon 172) mutation identified |
44 | IDH1 (codon 132) and IDH2 (codon 172) wt confirmed |
45 | Evidence of KLF4 K409Q and TRAF7 mutations |
46 | Evidence of wt KLF4 and TRAF7 |
47 | Evidence of MAP2K1 mutation |
48 | Evidence of wt MAP2K1 |
49 | Evidence of MET amplification |
50 | Evidence of MET normal copy number |
51 | Evidence of significant MGMT promoter methylation |
52 | Evidence of unmethylated MGMT promoter |
53 | Evidence of MYC/MYCN amplification |
54 | Evidence of MYC/MYCN normal copy number |
55 | Evidence of NF1 biallelic loss / mutation |
56 | Evidence of unaltered NF1 |
57 | Evidence of NF2 biallelic loss / mutation |
58 | Evidence of unaltered NF2 |
59 | Evidence of NKTR fusions |
60 | Evidence of native NKTR |
61 | Evidence of PTEN biallelic loss / mutation |
62 | Evidence of unaltered PTEN |
63 | Evidence of SDHB or SDHD mutation |
64 | Evidence of wt SDHB and SDHD |
65 | Evidence of SHH pathway activation |
66 | Evidence of normal SHH pathway |
67 | Evidence of inactivation of SMARCB1 (INI1 |
68 | Evidence of wt SMARCB1 (INI1) |
69 | Evidence of inactivation of SMARCA4 |
70 | Evidence of wt SMARCA4 |
71 | Evidence of TERT promotor mutation 7299 |
72 | Evidence of wt TERT promotor |
73 | Evidence of TP53 mutation |
74 | Evidence of wt TP53 |
75 | Evidence of TSC1 or TSC2 mutation |
76 | Evidence of wt TSC1 and TSC2 |
77 | Evidence of VHL mutation |
78 | Evidence of wt VHL gene |
79 | Evidence of WNT pathway activation |
80 | Evidence of normal WNT pathway |
81 | Evidence of WWTR1-CAMTA1 fusion |
82 | Evidence of native WWTR1 and CAMTA1 |
83 | Evidence of codeletion of chr.1p and chr.19q |
84 | Evidence of total chr.1p loss but normal copy number of chr.19q |
85 | Evidence of normal copy number of both chr.1p and chr.19q |
86 | Evidence of monosomy chr.6 |
87 | Evidence of chr.6 normal copy number |
88 | Evidence of polysomy chr.7 |
89 | Evidence of chr.7 normal copy number |
90 | Evidence of loss of chr.10 or chr.10q |
91 | Evidence of chr.10 normal copy number |
92 | Evidence of loss of chr.22 or chr.22q |
93 | Evidence of chr.22 or chr.22q normal copy number |
98 | Other (not listed) |
This attribute is also known by these names:
Context | Alias |
---|---|
plural | MOLECULAR DIAGNOSTIC CODES |